FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin

Absent mature data suggesting that Genentech's biomarker strategy would likely prove Avastin's efficacy in a subpopulation, ODAC members did not want to expose patients unnecessarily to a toxic agent for many years to come.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.